West Pharmaceutical (WST) Misses Q2 EPS by 5c; Adjusts FY11 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Join SI Premium – FREE
West Pharmaceutical Services, Inc. (NYSE: WST) reported Q2 EPS of $0.62, $0.05 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $307.9 million versus the consensus estimate of $299.45 million.
West Pharmaceutical Services, Inc. sees FY2011 EPS of $2.30-$2.40, versus prior guidance of $2.30-$2.50 and the consensus of $2.38. West Pharmaceutical Services, Inc. sees FY2011 revenue of $1.17-$1.20 billion, versus prior guidance of $1.16-$1.19 billion and the consensus of $1.18 billion.
West Pharmaceutical Services, Inc. sees FY2011 EPS of $2.30-$2.40, versus prior guidance of $2.30-$2.50 and the consensus of $2.38. West Pharmaceutical Services, Inc. sees FY2011 revenue of $1.17-$1.20 billion, versus prior guidance of $1.16-$1.19 billion and the consensus of $1.18 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
- Reynolds Consumer Products Inc. (REYN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
